Oscar Health, Inc. filings document the public-company disclosures of a healthcare technology and health insurance issuer listed on the New York Stock Exchange under Class A common stock symbol OSCR. Its Form 8-K reports cover operating results, guidance updates, Regulation FD disclosures, material agreements and capital-structure transactions, including credit facilities, convertible notes and debt exchanges.
The company’s proxy materials disclose annual meeting matters, board governance, director elections and executive compensation. Other filings address executive employment arrangements, registered securities, risk language tied to competition, artificial intelligence and machine-learning models, internal controls and the company’s use of technology to support Individual & Family plans, +Oscar services and related healthcare marketplace offerings.
Oscar Health, Inc. (OSCR) is the issuer for a planned resale of shares under Rule 144 by Mario T. Schlosser. A notice has been filed for the potential sale of 600,000 Class A shares of Oscar Health through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $18,205,505.85 and reference outstanding Class A shares of 273,469,000 as of August 27, 2026 on the NYSE. The shares are to be sold following a stock option exercise on a cash basis.
Over the prior three months, Mario T. Schlosser reported additional Rule 144 sales of Oscar Health Class A shares, including 34,120 shares for proceeds of $748,633.08 on June 2, 2026, 1,027,398 shares for $30,183,414.00 on June 23, 2026, and 47,500 shares for $1,484,013.80 on July 1, 2026.
Oscar Health, Inc. (OSCR) reported an insider transaction by Chief Financial Officer Richard Scott Blackley. On 2026-08-18, an entity associated with him, the MQB Irrevocable Trust, sold 18,750 shares of Class A Common Stock at a weighted average price of $31.74 per share. Following this sale, the trust held 56,250 shares indirectly, while Blackley also held 1,074,977 shares directly, which include shares to be issued upon vesting of one or more restricted stock units.
Oscar Health, Inc. (OSCR) received a notice that former affiliate Jeffery H. Boyd plans to sell up to 288,514 shares of Oscar common stock under Rule 144. The shares, to be sold on 11/12/2024, come from previously exercised options and are to be sold for cash through Morgan Stanley Smith Barney LLC.
The notice also lists prior Rule 144 sales of Oscar common stock by Boyd during the past three months, providing regulators and the market with transparency on recent and proposed share dispositions.
Oscar Health, Inc. (OSCR) is the issuer in a notice filed under Rule 144 covering planned sales of its common stock for the account of Chief Financial Officer Richard Scott Blackley, with Morgan Stanley Private Wealth Management listed as broker. The notice lists 18,750 shares of common stock to be sold and references restricted stock units vesting under a registered plan on 03/01/2024 and 12/01/2024. Recent activity disclosed includes multiple common stock sales during May and June 2026, and a remark states that certain shares were sold by the MQB Irrevocable Trust, with the notice signed by an attorney-in-fact for Blackley.
Jeffery H. Boyd filed a notice of proposed sale of up to 288,513 common shares of OSCR through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of 8,687,790.01, to be sold on or after 08/13/2026 on the NYSE. The shares relate to previously exercised options acquired from the issuer on 11/12/2024 for cash. In the past three months, Boyd reported two sales of OSCR common stock on 08/10/2026 totaling 251,036 shares for combined proceeds of 7,600,882.38.
Oscar Health, Inc. (OSCR) filed to potentially sell common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The notice lists up to 134,370 shares of common stock, with a stated value of $3,799,231.13, as eligible for sale on or after August 10, 2026.
The security relates to restricted stock vesting under a registered plan, with 134,370 shares shown as vesting on June 9, 2026 in connection with services rendered. The filing is a notice of proposed sale of restricted or control securities, not a confirmation that sales have occurred.
Oscar Health, Inc. reported strong improvement in results for the quarter ended June 30, 2026. Total revenue was 4,880,220 (in thousands), up from 2,863,945 a year earlier, and net income attributable to Oscar Health, Inc. was 361,808 (in thousands) compared with a loss of 228,361. For the first six months, revenue reached 9,527,414 (in thousands) and net income was 1,040,804.
Membership was about 3.0 million effectuated members as of June 30, 2026, approximately 46% higher than a year earlier. Operating cash flow rose to 4,711,325 (in thousands), supporting cash and cash equivalents of 4,075,612 and short-term investments of 4,479,906. Oscar also reports growing risk-adjustment payables and substantial balances due to CMS, extensive use of quota share and excess-of-loss reinsurance, and describes evolving ACA marketplace rules, subsidy changes, and new pharmaceutical tariffs that could influence future membership levels, premium dynamics, and medical cost trends.
Oscar Health reported record profitability in the first half of 2026. For Q2 2026, total revenue was $4,880,220 (in thousands) and net income attributable to Oscar Health, Inc. was $361,808 (in thousands), compared with a net loss of $228,361 (in thousands) a year earlier. Earnings from operations were $388,635 (in thousands) and Adjusted EBITDA reached $415,349 (in thousands). Medical loss ratio improved to 79.2% from 91.1%, and the SG&A expense ratio fell to 14.2% from 18.7%, helped by disciplined pricing, $164 million of favorable prior-period reserve development, and expense control.
For the first six months of 2026, net income attributable to Oscar Health, Inc. was $1,040,804 (in thousands) and Adjusted EBITDA was $1,142,421 (in thousands). Effectuated membership rose to 2,963,002 as of June 30, 2026. The company raised its full-year 2026 outlook, keeping total revenue guidance at $18.7–$19.0 billion but increasing expected earnings from operations to $500–$700 million and tightening MLR and SG&A expense ratio ranges. Cash and cash equivalents increased to $4,075,612 (in thousands), supporting a stronger balance sheet.
Gassen William reported acquisition or exercise transactions in this Form 4 filing.
Oscar Health, Inc. director William Gassen received a grant of 684 deferred stock units on July 9, 2026, as a compensation award in lieu of cash board retainer fees. Each unit represents a right to receive one share of Class A common stock and was valued at $31.20, the closing stock price on the grant date. The units are 100% vested at grant and will be settled in cash or shares, at the company’s discretion, within 45 days after specified events such as termination of service or a change in control. Following this grant, Gassen holds 7,071 deferred stock units directly.